Accelerating resistance, inadequate antibacterial drug pipelines and international responses.

摘要: a b s t r c The pandemic of multidrug-resistant (MDR) pathogens and their continuing spread is beyond dispute. In contrast to the past, today’s antibacterial research development (R&D) pipelines are nearly dry, failing provide flow novel antibiotics required match clinical challenges multidrug resistance crisis. Concerned over rapidly worsening potential global healthcare crisis caused by MDR bacteria lack robust drug pipelines, several multinational campaigns have issued policy recommendations initiated broad discussion with goal stimulating drugs technologies. These activities resulted in intensified co-operation between USA EU. recently announced extensive ‘Action plan against rising threats from antimicrobial resistance’ substantially ramps up action within recognising limited treatment options, European Commission decided on an unprecedented approach drive search for integrating pharmaceutical industry, capacities universities small companies supported public funding along pricing/reimbursement regulatory bodies. has shown leadership put plans place. Only future will tell whether these initiatives help curb impact